TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06436703

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza ModRNA Vaccine
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza ModRNA Vaccine
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza ModRNA Vaccine
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza ModRNA Vaccine
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza ModRNA Vaccine
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza ModRNA Vaccine
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza ModRNA Vaccine
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza ModRNA Vaccine
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza ModRNA Vaccine
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza ModRNA Vaccine
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza ModRNA Vaccine
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza ModRNA Vaccine
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza ModRNA Vaccine
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza ModRNA Vaccine
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Influenza Vaccine (QIV)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Influenza Vaccine (QIV)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Influenza Vaccine (QIV)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Influenza Vaccine (QIV)
Description: Intramuscular injection
Study: NCT06327399

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol 20 mg boluses till loss of contact

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol 20 mg boluses till loss of contact
Study: NCT06436703

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Influenza Vaccine (QIV)
Description: Intramuscular injection
Study: NCT04043468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audit and feedback
Description: Audit and feedback (A\&F) is an intervention that aims to improve professionals practices by providing professionals with a summary of their performance over a period of time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Audit and feedback
Description: Audit and feedback (A\&F) is an intervention that aims to improve professionals practices by providing professionals with a summary of their performance over a period of time.
Study: NCT05291338

Intervention type: DRUG
Intervention: Lipiodol
Description: Lipiodol dose should be over 5 ml if tumor diameter is less than 5 cm, and the maximum dose will be 10 ml when the tumor develops to more than 5 cm in diameter.
Study: NCT06582823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health belief model-based community educational program
Description: The 5-week intervention includes two weekly 60-minute face-to-face sessions for 8-10 participants, two weekly telephone follow-ups, and a booster session.~Week 1: Focuses on increasing knowledge about atrial fibrillation (AF), its risks, complications, and treatment benefits. The principal investigator (PI) provides education using interactive methods and colored visuals.~Week 2: Emphasizes skill building for pulse palpation to detect irregular pulses. Participants learn through demonstrations and practice using a simulated arm.~Weeks 3-4:Telephone follow-ups monitor adherence to pulse checking and address barriers. Support and advice are provided by the PI.~Week 5: A booster session reinforces knowledge and skills with scenario-based practice and use of a simulated arm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group will receive an information leaflet presenting information about AF, health risks and complications associated with AF, common methods to screen for AF, and follow-up actions if positive screening results are suspected.
Study: NCT05143099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEC
Description: tislelizumab（an anti-PD-1 monoclonal antibody）+cetuximab（monoclonal antibody against EGFR）+irinotecan
Study: NCT06310707

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ePatch ® Extended Wear Holter (EWH)
Description: Diagnostic Test: Extended ECG investigation~• An ambulatory ECG recordings with a duration of 7 days using Philips ePatch (https://www.myheartmonitor.com/device/epatch/) will be applied
Study: NCT06582472

Intervention type: PROCEDURE
Intervention: Ophthalmological examination including imaging assessments
Description: Ophthalmological examination including imaging assessments (SD-OCT, Spectral Domain Optical Coherence Tomography, a procedure to study and quantify possible retinal neurodegeneration and OCT-A, Optical coherence tomography angiography, a procedure to study and quantify possible retinal vascular abnormalities)

Intervention type: PROCEDURE
Intervention: Ophthalmological examination including imaging assessments
Description: Ophthalmological examination including imaging assessments (SD-OCT, Spectral Domain Optical Coherence Tomography, a procedure to study and quantify possible retinal neurodegeneration and OCT-A, Optical coherence tomography angiography, a procedure to study and quantify possible retinal vascular abnormalities)

Intervention type: PROCEDURE
Intervention: Ophthalmological examination including imaging assessments
Description: Ophthalmological examination including imaging assessments (SD-OCT, Spectral Domain Optical Coherence Tomography, a procedure to study and quantify possible retinal neurodegeneration and OCT-A, Optical coherence tomography angiography, a procedure to study and quantify possible retinal vascular abnormalities)

Intervention type: PROCEDURE
Intervention: Ophthalmological examination including imaging assessments
Description: Ophthalmological examination including imaging assessments (SD-OCT, Spectral Domain Optical Coherence Tomography, a procedure to study and quantify possible retinal neurodegeneration and OCT-A, Optical coherence tomography angiography, a procedure to study and quantify possible retinal vascular abnormalities)

Intervention type: PROCEDURE
Intervention: confocal analysis of cornea
Description: Confocal analysis of cornea: a procedure to study and quantify possible corneal nerve degeneration as a marker of involvement of diabetic neuropathy

Intervention type: PROCEDURE
Intervention: confocal analysis of cornea
Description: Confocal analysis of cornea: a procedure to study and quantify possible corneal nerve degeneration as a marker of involvement of diabetic neuropathy
Study: NCT05184868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT247
Description: Ultra rapid acting prandial insulin aspart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AT247
Description: Ultra rapid acting prandial insulin aspart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AT247
Description: Ultra rapid acting prandial insulin aspart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NovoLog
Description: Rapid acting prandial insulin aspart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NovoLog
Description: Rapid acting prandial insulin aspart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NovoLog
Description: Rapid acting prandial insulin aspart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fiasp
Description: Fast acting prandial insulin aspart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fiasp
Description: Fast acting prandial insulin aspart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fiasp
Description: Fast acting prandial insulin aspart
Study: NCT04505007

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specialized heart function clinic
Description: This information has already been provided.
Study: NCT05932420

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 16.4g pure medium triglyceride oil mixed with 1 mM of bitter sucrose octaacetate. A dose of 25g of the placebo drink is provided immediately after each training session and 30 minutes before sleeptime throughout the training period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone ester
Description: A dose of 25g of ketone ester after each training session and 30 minutes before sleeptime throughout the training period.
Study: NCT05430724

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Controlled hypotention
Description: The procedure to be applied to the cases to be included in the study:~Patients randomized by the sealed envelope method will be divided into 2 groups (40 patients in each group).~The sealed envelopes that determine which group the patient will belong to will be randomly selected by the patient.~Standard general anesthesia will be applied to all patients. Before starting the surgical procedure; Group N (Nicardipine infusion) will be administered at a dose of 5-15mg/h, and Group E (Esmolol infusion) at a dose of 50-300mcg/kg/min.~2) General anesthesia will be applied to all groups. Patients will be administered controlled hypotension (mean arterial pressure 50-60 mmHg).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Controlled hypotention
Description: The procedure to be applied to the cases to be included in the study:~Patients randomized by the sealed envelope method will be divided into 2 groups (40 patients in each group).~The sealed envelopes that determine which group the patient will belong to will be randomly selected by the patient.~Standard general anesthesia will be applied to all patients. Before starting the surgical procedure; Group N (Nicardipine infusion) will be administered at a dose of 5-15mg/h, and Group E (Esmolol infusion) at a dose of 50-300mcg/kg/min.~2) General anesthesia will be applied to all groups. Patients will be administered controlled hypotension (mean arterial pressure 50-60 mmHg).
Study: NCT05984485

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant chemotherapy plus total mesorectal excision
Description: Neoadjuvant chemotherapy regimen recommended FOLFOX6, XELON, FOLFOX, mFOLFOX for 4-6 courses, and TME surgical treatment after preoperative tumor restaging 1-2 weeks after neoadjuvant chemotherapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total mesorectal excision
Description: Standard total mesorectal excision
Study: NCT06583356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: Participants will receive motivational interviewing intervention previously, delivered face-to-face at participants' home, 1 session, followed by 2 brief follow-up sessions. Each session is expected to last approximately 30 to 45 minutes.
Study: NCT06582472

Intervention type: PROCEDURE
Intervention: blood sampling collection
Description: collection and analysis of blood samples to identify diabetic retinopathy biomarkers and early abnormalities of the vascular retinal system.
Study: NCT06582459

Intervention type: DEVICE
Intervention: HFNC treatment
Description: HFNC treatment HFNC therapy. The initial flow rate of 50-60 L/min was subsequently adjusted to maintain an oxygen saturation (SpO2) ≥92%. The FiO2 was titrated to maintain the PaO2 between 60 and 80 mmHg.

Intervention type: DEVICE
Intervention: NIV treatment
Description: NIV treatment A Mindray SV300 ventilator (Mindray Medical International Limited, Shenzhen, China) was used to deliver NIV via an oronasal mask. The initial inspiratory positive airway pressure (IPAP) was 12-15 cmH2O and adjusted later to achieve a tidal volume of 6-8 mL/kg of predicted body weight and a respiratory rate of \&amp;lt;30 breaths/min. The expiratory positive airway pressure (EPAP) was established at 5-8 cmH2O. Additional-ly, FiO2 was titrated to maintain a PaO2 between 60 and 80 mmHg.
Study: NCT06581276

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Acceptance and Commitment Therapy (ACT)
Description: Acceptance and Commitment Therapy (ACT) is an evidence-based behavioral pain treatment intervention for Chronic Pain, anxiety and depression, and substance use disorders, being studied as a group-based therapy delivered by substance use counselors in an opioid treatment program.
Study: NCT06582394

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Exp Group
Description: Balance and coordination were targeted through virtual stepping tasks, where participants practiced stepping in various directions to improve postural control and lower limb function. Additionally, they performed virtual balance exercises by standing on simulated platforms of varying stability. For gait and mobility, participants practiced walking in a virtual environment with real-time feedback to correct gait abnormalities. They also encountered virtual obstacles, which required them to adapt their walking patterns and improve mobility. In this study, both the intervention and control groups underwent a 6-week treatment plan consisting of 5 sessions per week, with each session lasting 45 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: For gait training, participants practiced walking on flat surfaces, sometimes with the assistance of parallel bars or walking aids, to improve their walking speed, step length, and rhythm. They also performed sit-to-stand exercises to strengthen the lower limbs and improve mobility for daily activities. Additionally, manual therapy techniques, such as joint mobilizations and stretching, were applied to reduce spasticity and increase range of motion in the affected limbs. Both treatment groups progressed based on individual capabilities, with therapists adjusting exercises accordingly throughout the study. In this study, both the intervention and control groups underwent a 6-week treatment plan consisting of 5 sessions per week, with each session lasting 45 minutes.
Study: NCT05825443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Patients received four 21-day cycles of chemotherapy (decided by the researcher) combined with camrelizumab (200 mg in day 1), followed by maintenance with camrelizumab (200 mg in day 1, q3w), until one year or the disease progressed or unacceptable toxicity.
Study: NCT06173167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crowns self-adhesively luted
Description: After cavity preparation, the zirconia chairside crown will be placed using SpeedCEM Plus. The excess will be light cured with Bluephase G4 in PreCure mode (950 mW/cm\^2). After removal of the excess, the luting material margins will be light-cured again for 20s (1200 mW/cm\^2).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crowns conventionally cemented
Description: After cavity preparation, the zirconia chairside crown will be placed using ZirCAD Cement. The excess cement will be removed in the gel phase, either following light curing (5 - 10 seconds per segment) or following self-curing (approximately 2 min after placement). The restoration will be held in position during final curing that is complete 4 min 30 s after placement.
Study: NCT05731440

Intervention type: DRUG
Intervention: 18F-Fluselenamyl
Description: Participants will receive a single intravenous bolus injection of 10 mCi ± 20% of the investigational radiotracer 18F-Fluselenamyl and will undergo an 18F-Fluselenamyl PET/CT scan.

Intervention type: DRUG
Intervention: 18F-Fluselenamyl
Description: Participants will receive a single intravenous bolus injection of 10 mCi ± 20% of the investigational radiotracer 18F-Fluselenamyl and will undergo an 18F-Fluselenamyl PET/CT scan.
Study: NCT05451628

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Default CI fitting
Description: Programming of cochlear implant speech processor according to standard clinical care

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomy-based CI fitting
Description: Programming of cochlear implant speech processor with anatomy-based fitting
Study: NCT05477043

Intervention type: DIAGNOSTIC_TEST
Intervention: Transabdominal ultrasound and cistoscopy
Description: Ultrasound detection of the bilateral ureteral jets vs absence of the ureteral jet on one side compared with the presence of bilateral ureteral jet on cystoscopy vs absence on one side.
Study: NCT05183880

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phosphatidylcholine-lipid encapsulated vitamin C
Description: Ingesting 1000 mg of vitamin C in phosphatidylcholine-lipid encapsulated form

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Crystalline vitamin C
Description: Ingesting 1000 mg of vitamin C in crystalline form
Study: NCT05462041

Intervention type: OTHER
Group type: OTHER
Intervention: DBD Donor Heart Transplantation
Description: A technique of donor heart procurement.

Intervention type: DEVICE
Group type: OTHER
Intervention: DCD Donor Heart Transplantation
Description: A technique of donor heart procurement. The TransMedics' OCS Heart technology is the only portable system available for ex-vivo maintenance of the donor heart in a metabolically active and beating state. It is currently FDA approved for procurement and transport.
Study: NCT06387355

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Coronary computed topography (CT) angiography with FFR-CT
Description: The investigational treatment strategy will have a coronary CT angiography diagnostic imaging with computational analysis FFR-CT (Fractional Flow Reserve from the coronary CTA)
Study: NCT06583122

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Approach
Description: All enrolled patients will receive the new ultrasound-guided approach to occipital nerve radiofrequency ablation
Study: NCT06264063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: control group
Description: the investigators have to assess the neuropsychological and psychological profile with specific questionnaire that evaluated the moral index, presence of obsessive and compulsive disorders and Montreal Cognitive Assessment to evaluate cognitive functions
Study: NCT00816205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coated Nifedipine Suppositories
Description: Subjects will take rectally a total of 3 Coated Suppositories per study. 90 minutes after each coated suppository insertion this suppository will be removed and a amnometric study will be performed:~The first dose will contain 4 mg of Nifedipine and the manomentric measurement performed afterwards will be used to determine baseline anal pressures.~The second dose will contain 12 mg of Nifedipine. The third dose will contain 24 mg of Nifedipine.
Study: NCT05107258

Intervention type: DIAGNOSTIC_TEST
Intervention: The Pine Trees Health Test System
Description: Consists of the Pine Trees Health Reader and the Pine Trees Health COVID-19 Test Kit, which contains the Pine Trees Health Cartridge, Pine Trees Health Sample Vial containing Sample Lysis Buffer and the Pine Trees Health Nasal Swab (anterior nares) for collection. The Test System is a point-of-care test used for the qualitative detection of nucleic acid from SARS-CoV-2 viral RNA in nasal swabs taken from individuals who are suspected by a healthcare professional of having COVID-19. The COVID-19 test is a rapid molecular, in vitro diagnostic test using isothermal nucleic acid amplification technology and detection of the resulting amplicon using CRISPR-mediated collateral reporter unlocking.
Study: NCT05409872

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combination of Epigallocatechin gallate, vitamin D, vitamin B6, and D-Chiro-inositol
Description: The subject takes a combination of 333.35 mg of green tea extract (150 mg of Epigallocatechin gallate), 25 mg of D-Chiro-inositol, 25 mcg of Vitamin D, and 5 mg of Vitamin B6 twice a day for three months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subject takes the placebo twice a day for three months.
Study: NCT06264063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: experimental group
Description: the investigators have to assess the neuropsychological and psychological profile with specific questionnaire that evaluated the moral index, presence of obsessive and compulsive disorders and Montreal Cognitive Assessment to evaluate cognitive functions
Study: NCT05066971

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Self-adjustment of medication
Description: Each week, based on the information provided by HM (heart rate and hours of activity each day), the rate control medication is adjusted to increase the total of activity time.
Study: NCT06473194

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general anesthesia drug (like Propofol, esmeron, and ketamin, .effects of pneumoperitoneum
Description: this research will involve the selection of elective cases with ASA class I or II and assessment of patients with respiratory cardiovascular parameters and hematology perioperative
Study: NCT04794790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Description: Buprenorphine/Naloxone induction via a standard dose protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Description: Buprenorphine/Naloxone induction via a standard dose protocol
Study: NCT04832464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RACE Protocol: Balance training along with resistance, aerobic and cognitive exercises.
Description: therapy for the preservation, enhancement, or restoration of movement and physical function impaired or threatened by disease, injury, or disability that utilizes therapeutic exercise, physical modalities (such as massage and electrotherapy), assistive devices, and patient education and training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RACE Protocol: Balance training along with resistance, aerobic and cognitive exercises.
Description: therapy for the preservation, enhancement, or restoration of movement and physical function impaired or threatened by disease, injury, or disability that utilizes therapeutic exercise, physical modalities (such as massage and electrotherapy), assistive devices, and patient education and training.